/
Markets
Crypto
News
Forecasts
Forex Brokers
Calendars
Macro Data
About us
Commodity Prices
Currency Rates
Cryptocurrency Prices
Global Market Indices
Stock Prices
ETF Prices
Cryptocurrency Prices
Crypto Exchanges
Crypto Wallets
Cryptocurrency News
Cryptocurrency Forecasts
Commodity News
Forex News
Crypto News
Stock Market News
Economic News
Opinions
Broker News
Commodities
Forex
Crypto
Indices
Natural Gas Forecasts
Gold Forecasts
WTI Crude Oil Forecasts
S&P 500 Forecasts
Forex Brokers Reviews
Best Brokers Guides
Compare Forex Brokers
Best Forex Brokers
Best Forex Platforms
Best MT4 Brokers
Best for Trading Gold
Best Brokers in Australia
Best Brokers for Beginners
Best Brokers in UK
Brokers Promotions
Stock Brokers
Economic Calendar
Earnings Calendar
Splits Calendar
Dividends Calendar
Holiday Calendar
IPO Calendar
Stock Screener
Currency Converter
Global Macro indicators
Sovereign Credit Ratings
Global Major Indicators
Interest Rates
United States Indicators
China Indicators
Australia Indicators
Euro Area Indicators
About us
Contact Us
Terms Of Use
Become A Contributer
EUR/USD
+0.32%
Natural Gas
-0.40%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.20%
VIX
N/A
Economic Calendar
EUR/USD
+0.32%
Natural Gas
-0.40%
Gold
N/A
BTC
N/A
ETH
N/A
SPX
+1.20%
VIX
N/A
Economic Calendar
BTC
N/A
ETH
N/A
XRP
N/A
ADA
N/A
SOL
N/A
Review
Review
Review
Tesla Faces Steepest Revenue Drop Since 2012 Amid Market Challenges
about 11 hours ago
Composite PMI Drops To 50.9, Missing Analyst Expectations
about 18 hours ago
German Services PMI Rises to a 10-Month High 53.3 in April
about 24 hours ago
Gold Prices at a Crossroads: Indicators Signal Caution
1 day ago
The Week Ahead: US Inflation, Private Sector PMIs, and the Bank of Japan in Focus
3 days ago
Will Next Week’s Big Tech Earnings Reinvigorate the Market?
4 days ago
EUR/USD, GBP/USD, DXY Price Forecast: DXY Dips Below 106; Market Correction Ahead?
6 minutes ago
Understanding Bitcoin’s Fourth Halving: Valuable Insights for Investors
19 minutes ago
Silver (XAG) Daily Forecast: Dips to $27.15; Will Trendline Spur Buying?
41 minutes ago
Gold (XAU) Daily Forecast: Eyes on $2333 Pivot as Dollar Weakens
about 1 hour ago
Natural Gas and Oil Forecast: US Stock Decline Spurs Price Surge; Buy Today?
about 2 hours ago
DAX Index Today: Eyes on German Business Climate and US Core Durable Goods
about 5 hours ago
Quick Links
:
Forecasts
Economic Calendar
Commodities
Trade Now
ad
ad
Advertisement
Advertisement
home
stocks
HALO
profile
Halozyme Therapeutics Inc.
Follow
HALO
(
Nasdaq - US
)
Open
38.96
+0.25 (+0.65%)
in
:
usd
•
As of: Apr 23, 2024 15:59
UTC -4
Open
38.73
High
39.42
Low
38.71
Overview
News & Analysis
Profile
Financials
Advanced Chart
History
Earnings
About
Halozyme Therapeutics Inc.
CEO
Helen I. Torley
Headquarters
12390 el camino real
san diego, ca 92130, united states
Auditor
Ernst & Young LLP
Employees
373
Share Holders
72,264
Website
www.halozyme.com
Industry
biotechnology
Sector
health technology
Company Overview
Halozyme Therapeutics Inc. is a biopharmaceutical company, focused on the development and commercialization of novel treatments for oncology indications by targeting tumor microenvironment. The company's ENHANZE drug delivery technology helps in developing subcutaneous formulation of drugs. The company also licenses its novel drug delivery technology, ENHANZE. Several companies including Roche, Takeda, J&J, AbbVie, Lilly, Bristol-Myers and others are using this technology for developing subcutaneous formulation of their currently marketed drugs. It also recognizes revenues from sale of drug products to its collaboration partners for development of drugs using its ENHANZE platform. The company also has one approved product in its portfolio, Hylenex recombinant as an adjuvant to facilitate subcutaneous fluid administration. Although Halozyme has one marketed product, it derives the majority of its revenues from royalties on sales of partnered drugs.
Halozyme Therapeutics Inc.
Statistics
Valuation Measures
Market Capitalization
2
4.95B
Enterprise Value
6.33B
Enterprise Value/EBITDA
(ttm)
14.95
Price to Earnings Ratio
(ttm)
15.15
Price to Book
(mrq)
60.90
Price to Sales
(ttm)
5.92
Price to Cash
(ytd)
12.16
Profitability
Gross Margin
(ttm)
76.89%
Operating Margin
(ttm)
41.15%
Profit Margin
(ttm)
33.31%
Return on Equity
(ttm)
248.20%
Return on Invested Capital
(ttm)
17.16%
Return on Assets
(ttm)
19.13%
Income Statement
Revenue
(ttm)
829.25M
Revenue Per Share
(ttm)
6.54
Gross Profit
(ttm)
636.89M
EBITDA
(ttm)
3
423.41M
Net Income Avi to Common
(ttm)
281.59M
Diluted EPS
(ttm)
2.11
Share Statistics
Beta (5Y Monthly)
1.25
52-Week Change
16.16%
S&P500 52-Week Change
22.56%
S&P500 Member
No
Stock Optionable
Yes
Total Shares Outstanding
1
126.82M
Dividend Yield
0.00%
Float
4
123.62M
%
Held by Insiders
2.70%
%
Held by Institutions
97.79%
Balance Sheet
Total Cash
(mrq)
336.00M
Total Cash Per Share
(mrq)
2.65
Total Debt
(mrq)
1.50B
Total Debt/Equity
(mrq)
1788.91%
Current Ratio
(mrq)
6.64%
Quick Ratio
(mrq)
5.50%
Book Value Per Share
(mrq)
0.66
Cash Flow
Operating Cash Flow Per Share
(ytd)
2.90
Free Cash Flow
(ytd)
373.28M
Table Key
mrq
=
Most Recent Quarter
ttm
=
Trailing Twelve Months
ytd
=
Year To Date
Footnotes
Data provided by Zacks Investment Research or calculated by FXEmpire. Stock price provided by Xignite. All numbers are rounded to the closest decimal.
1
Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2
Market Cap is calculated using total shares outstanding and the most recent share price.
3
EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4
The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.
Sponsored
Sponsored
This Section / Page contains links to the 3rd party websites of our top partners from whom we may receive compensation.
Trade With A Regulated Broker